Работы, на которые ссылается эта работа
Работ: 205
Работа: Viral modulation of the CXCL12/CXCR4/CXCR7 axis: mechanisms, impacts on immunity and oncogenesis, and therapeutic opportunities
Dna Damage Response Alterations in Gastric Cancer: Knocking down a New Wall
Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
Статья2021Цитирований: 3ABICXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway
Zhongxing Liang, Joann Brooks, Margaret Willard +4
Статья2007Цитирований: 2ABICXCR4: A virus’s best friend?
Kathleen L. Arnolds, Juliet V. Spencer
Обзорная статья2014Цитирований: 2ABICXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher, Simon P. Fricker
Обзорная статья2010Цитирований: 2ABICXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
Xueqing Sun, Guangcun Cheng, Mingang Hao +6
Обзорная статья2010Цитирований: 2ABIMolecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment
Обзорная статья2015Цитирований: 2ABISmall Molecule Inhibitors of CXCR4
Bikash Debnath, Shili Xu, Fedora Grande +2
Обзорная статья2013Цитирований: 2ABIRelevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions
Christine Huynh, Jasper Dingemanse, Henriette E. Meyer zu Schwabedissen +1
Обзорная статья2020Цитирований: 2ABIThe Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
Yi Shi, David J. Riese, Jianzhong Shen
Обзорная статья2020Цитирований: 2ABICXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications
Yaru Yang, Jiayan Li, Wangrui Lei +10
Обзорная статья2023Цитирований: 2ABILeukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19
R. Alon, Mike Sportiello, Stav Kozlovski +5
Обзорная статья2020Цитирований: 2ABIThe CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
Sara K. Daniel, Yongwoo David Seo, Venu G. Pillarisetty
Обзорная статья2019Цитирований: 2ABIImmunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment
Raffaele De Luca, Luca Gianotti, Paolo Pedrazzoli +13
Обзорная статья2022Цитирований: 2ABIReal-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin Myint +63
Статья2023Цитирований: 2ABIImmune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Muhammad Tufail, Canhua Jiang, Ning Li
Обзорная статья2025Цитирований: 2ABI